Weed control in soybean (Glycine max L.) through resource management strategies and its influence on yield and nutrient uptake

A field experiment was conducted during kharif season of 2011 at Research Farm, Sher-e-Kashmir University of Agricultural Sciences and Technology, Chatha, Jammu to evaluate the effect of weed management prac-tices on yield and nutrient uptake of soybean utilizing different resource management strategies. The lowest weed density and dry matter of weeds was recorded with hand weeding at 15 and 35 days after sowing (DAS) which was equally effective as imazethapyr @ 75 g ha -1 (PoE) fb hoeing at 35 DAS and quizalofop-ethyl @ 40 g ha-1 (PoE) fb hoeing at 35 DAS. All weed control treatments had significant effect on yield and nutrient up-take of soybean. Among the different weed control treatments, lowest N, P and K uptake by weeds were recorded in hand-weeding (15 and 35 DAS) which was statistically at par with imazethapyr @ 75 g ha -1 fb hoeing at 35 DAS. The maximum uptake by seed and straw were recorded in weed free which was statistically at par with twice hand weeding at 15 and 35 DAS, imazethapyr @ 75 g ha-1 fb hoeing at 35 DAS and quizalofop-ethyl @ 40 g ha-1 fb hoeing at 35 DAS. The highest seed and straw yield of soybean was harvested with hand-weeding (15 and 35 DAS) followed by imazethapyr @ 75 g ha -1 fb hoeing at 35 DAS. For the first time, soybean crop has been introduced in Jammu region for research purpose. Weed management varies with agro-climatic conditions. The study would be helpful to understand weed menace in this particular climatic condition of Jammu and to manage them combinedly and efficiently

Psychosis as the sole presenting feature of hyperthyroidism: a case report

Thyroid disease is a very common entity with a wide range of presentation, We report a case of twenty six year old female presented to emergency room with frank psychosis over the course of her stay in hospital we investigated thoroughly and finally she turned out to be a case of hyperthyroidism with psychosis as the only presenting symptom and after starting her on carbimazole patient responded to the treatment remarkably

In vitro cytotoxicity and catalytic evaluation of dioxidovanadium(V) complexes in an azohydrazone ligand environment

Three new anionic dioxidovanadium(V) complexes (HNEt3)[VO2(L)1–3] (1–3) of tridentate binegative aroylhydrazone ligands containing the azobenzene moiety were synthesized and structurally characterized. The aroylhydrazone ligands (H2L1–3) were derived from the condensation of 5-(arylazo) salicylaldehyde derivatives with the corresponding aroyl hydrazides. All the synthesized ligands and metal complexes were successfully characterized by several physicochemical techniques, namely, elemental analysis, electrospray ionization mass spectrometry, spectroscopic methods (IR, UV-vis and NMR), and cyclic voltammetry. Single-crystal X-ray diffraction crystallography of 1–3 revealed five-coordinate geometry, where the ligand coordinates to the metal centre in a binegative tridentate O, N, O coordinating anion and two oxido-O atoms, resulting in distortion towards the square pyramidal structure. The complexes were further evaluated for their in vitro cytotoxicity against HeLa and HT-29 cancer cell lines. All the complexes manifested a cytotoxic potential that was found to be comparable with that of clinically referred drugs, while complex 3 proved to be the most cytotoxic among the three complexes for both cell lines, which may be due to the synergistic effect of the naphthyl substituent in the azohydrazone ligand environment coordinated to the vanadium metal. The synthesized complexes 1–3 were probed as catalysts for the oxidative bromination of thymol and styrene as a functional mimic of vanadium haloperoxidases (VHPOs). All the reactions provided high percentages of conversion (>90%) with a high turnover frequency (TOF) in the presence of the catalysts 1–3. In particular, for the oxidative bromination of thymol, the percentage of conversion and TOF were in the ranges of 98–99% and 5380–7173 (h−1), respectively. Besides, 3 bearing the naphthyl substituent showed the highest TOF among all the complexes for the oxidative bromination of both thymol and styrene

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach. Methods Samples from 84 patients derived from two neoadjuvant AI therapy trials were subjected to copy number profiling by microarray-based comparative genomic hybridisation (aCGH, n = 84), gene expression profiling (n = 47), matched pre- and post-AI aCGH (n = 19 pairs) and Ki67-based AI-response analysis (n = 39). Results Integrative analysis of these datasets identified a set of nine genes that, when amplified, were associated with a poor response to AIs, and were significantly overexpressed when amplified, including CHKA, LRP5 and SAPS3. Functional validation in vitro, using cell lines with and without amplification of these genes (SUM44, MDA-MB134-VI, T47D and MCF7) and a model of acquired AI-resistance (MCF7-LTED) identified CHKA as a gene that when amplified modulates estrogen receptor (ER)-driven proliferation, ER/estrogen response element (ERE) transactivation, expression of ER-regulated genes and phosphorylation of V-AKT murine thymoma viral oncogene homolog 1 (AKT1). Conclusions These data provide a rationale for investigation of the role of CHKA in further models of de novo and acquired resistance to AIs, and provide proof of concept that integrative genomic analyses can identify biologically relevant modulators of AI response

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility. Methods A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1wt or ESR1Y537S, modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies. Results Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops associated with RAD001. Conclusions Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER

Ten years survival results of randomized study comparing weekly vs. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix

Background: The current standard of treatment for locally advanced cervical cancer is concurrent chemo-radiation with improved overall survival (OS) by 6% with manageable toxicities. The cisplatin 40 mg/m2 given weekly is the widely practiced regimen for 4–6 cycles concurrently with irradiation. Materials and methods: Two hundred and twelve patients with histologically proven squamous cell carcinoma of cervix with stages IIB to IIIB were enrolled between 2007–2011. External beam radiation dose of 45 Gy in 25 fractions was delivered over 5 weeks. Brachytherapy was delivered by manual afterloading cesium-137 (Cs137) low dose brachytherapy (LDR) using modified Fletcher suit intracavitary applicators to a total dose of 30 Gy to Point A or interstitial template to dose of 21 Gy/3 fractions with remote afterloading iridium-192 (Ir192) high dose brachytherapy (HDR). Patients were randomized to arm A receiving 40 mg/m2 of concurrent cisplatin weekly and arm B receiving 100 mg/m2 of concurrent cisplatin triweekly. Results: One hundred and nine patients were randomized to weekly cisplatin and one hundred and three patients to triweekly cisplatin at the end of recruitment. At ten years, the OS was higher in the weekly arm (79.8%) compared to triweekly arm (70.9%). Disease free survival (DFS) was almost equal (76.1% and 73.8%) in the weekly and three-weekly arms. There is definite significance in overall DFS with patients receiving the cumulative cisplatin doses of more than 250 mg (p = 0.028). The patients with more than 45 years of age had better overall survival (OS) (79%) with statistical significance 31 (p = 0.020). Conclusion: Both cisplatin based triweekly and weekly concurrent chemotherapy are equally effective in terms of OS and DFS

Gendering Farmer Producer companies at the Agricultural Frontier of India: Empowerment or Burden?

Farmer Producer Companies (FPCs) are driving agricultural frontier expansions in India. Their main objectives are to mobilize small-scale farmers to collectivize and organize in order to gain collective bargaining power, in the process empowering farmers and eliminating middlemen. However, they have not established any demonstrable success in achieving these goals. This chapter seeks firstly, to draw transnational connections between agro-ecological transformations in India and larger market/capital expansions through FPCs, contextualized amidst national development goals for farmer empowerment, changing labor patterns, and ecological degradation. In doing so, it will, secondly, explore the gendered dimension of FPCs in India by analyzing how the process of establishing women-only FPCs by using mandatory inclusion as a participation tool can serve to disempower and further burden women. While mandatory involvement of women farmers on their Board of Directors as an empowerment strategy can prove crucial to enhancing women’s decision-making roles, this chapter asks whether such an inclusionary approach remains meaningful to achieve FPC success in a context where external support for women’s empowerment is not provided

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Introduction Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgically with the aromatase inhibitor anastrazole with those from MCF7 cells adapted to long-term oestrogen deprivation (LTED) (2) to assess the clinical value of selected genes in public clinical data sets and (3) to determine the impact of targeting these genes with novel agents. Methods Gene expression and Ki67 data were available from 69 postmenopausal women with oestrogen receptor–positive (ER+) early BC, at baseline and 2 weeks after anastrazole treatment, and from cell lines adapted to LTED. The functional consequences of target genes on proliferation, ER-mediated transcription and downstream cell signalling were assessed. Results By intersecting genes predictive of a poor change in Ki67 with those upregulated in LTED cells, we identified 32 genes strongly correlated with poor antiproliferative response that were associated with inflammation and/or immunity. In a panel of LTED cell lines, C-X-C chemokine receptor type 7 (CXCR7) and CXCR4 were upregulated compared to their wild types (wt), and CXCR7, but not CXCR4, was associated with reduced relapse-free survival in patients with ER+ BC. The CXCR4 small interfering RNA variant (siCXCR4) had no specific effect on the proliferation of wt-SUM44, wt-MCF7 and their LTED derivatives. In contrast, siCXCR7, as well as CCX733, a CXCR7 antagonist, specifically suppressed the proliferation of MCF7-LTED cells. siCXCR7 suppressed proteins associated with G1/S transition and inhibited ER transactivation in MCF7-LTED, but not wt-MCF7, by impeding association between ER and proline-, glutamic acid– and leucine-rich protein 1, an ER coactivator. Conclusions These data highlight CXCR7 as a potential therapeutic target warranting clinical investigation in endocrine-resistant BC

Potential health risks of complementary alternative medicines in cancer patients

Many cancer patients use complementary alternative medicines (CAMs) but may not be aware of the potential risks. There are no studies quantifying such risks, but there is some evidence of patient risk from case reports in the literature. A cross-sectional survey of patients attending the outpatient department at a specialist cancer centre was carried out to establish a pattern of herbal remedy or supplement use and to identify potential adverse side effects or drug interactions with conventional medicines. If potential risks were identified, a health warning was issued by a pharmacist. A total of 318 patients participated in the study. Of these, 164 (51.6%) took CAMs, and 133 different combinations were recorded. Of these, 10.4% only took herbal remedies, 42.1% only supplements and 47.6% a combination of both. In all, 18 (11.0%) reported supplements in higher than recommended doses. Health warnings were issued to 20 (12.2%) patients. Most warnings concerned echinacea in patients with lymphoma. Further warnings were issued for cod liver/fish oil, evening primrose oil, gingko, garlic, ginseng, kava kava and beta-carotene. In conclusion, medical practitioners need to be able to identify the potential risks of CAMs. Equally, patients should be encouraged to disclose their use. Also, more research is needed to quantify the actual health risks

Comparative Assessment of Copper, Iron, and Zinc Contents in Selected Indian (Assam) and South African (Thohoyandou) Tea (Camellia sinensis L.) Samples and Their Infusion: A Quest for Health Risks to Consumer

The current study aims to assess the infusion pattern of three important micronutrients namely copper (Cu), iron (Fe), and zinc (Zn) contents from black tea samples produced in Assam (India) and Thohoyandou (South Africa). Average daily intakes and hazardous quotient were reported for these micronutrients. Total content for Cu, Fe, and Zn varied from 2.25 to 48.82 mg kg−1, 14.75 to 148.18 mg kg−1, and 28.48 to 106.68 mg kg−1, respectively. The average contents of each of the three micronutrients were higher in tea leaves samples collected from South Africa than those from India while the contents in tea infusions in Indian samples were higher than in South African tea samples. Results of this study revealed that the consumption of 600 mL tea infusion produced from 24 g of made tea per day may be beneficial to human in terms of these micronutrients content. Application of nonparametric tests revealed that most of the data sets do not satisfy the normality assumptions. Hence, the use of both parametric and nonparametric statistical analysis that subsequently revealed significant differences in elemental contents among Indian and South African tea